CIK 0001403708
EVOK Evoke Pharma Inc
Insider trading from SEC Form 4. Last filing Dec 19, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at Evoke Pharma Inc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | Roger M. Klein owner sell | $96k 9,000 shares | -26% | - | |
| 12Weak | Nantahala Capital Management, LLC owner sell | $180 41 shares | -0% | - |
Transactions
The last 60 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 17, 2025 | Nantahala Capital Management, LLC owner | JOther Common Stockindirect: See Footnote | -148,153 | $11.00 | $1.6M | 0 | Dec 19, 2025 |
| Dec 17, 2025 | Nantahala Capital Management, LLC owner | JOther Prefunded Warrantsderivativeindirect: See Footnote | -433,962 | $11.00 | $4.8M | 0 | Dec 19, 2025 |
| Dec 17, 2025 | Nantahala Capital Management, LLC owner | JOther Series A Common Stock Purchase Warrantsderivativeindirect: See Footnote | -117,019 | $4.71 | $551k | 0 | Dec 19, 2025 |
| Dec 17, 2025 | Nantahala Capital Management, LLC owner | JOther Series C Common Stock Purchase Warrantsderivativeindirect: See Footnote | -117,019 | $4.71 | $551k | 0 | Dec 19, 2025 |
| Dec 17, 2025 | Nantahala Capital Management, LLC owner | JOther Amended Series A Common Stock Purchase Warrantsderivativeindirect: See Footnote | -158,531 | $10.99 | $1.7M | 0 | Dec 19, 2025 |
| Dec 17, 2025 | Nantahala Capital Management, LLC owner | JOther Amended Series C Common Stock Purchase Warrantsderivativeindirect: See Footnote | -250,627 | $10.99 | $2.8M | 0 | Dec 19, 2025 |
| Dec 16, 2025 | Malcolm R Hill director | UTender of shares Common Stock | -133 | - | - | 0 | Dec 17, 2025 |
| Dec 16, 2025 | Mark Kowieski Chief Financial Officer | UTender of shares Common Stock | -11,815 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Vickie S Reed director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,250 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Greg Pyszczymuka director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,833 | - | - | 0 | Dec 17, 2025 |
| Dec 16, 2025 | Matthew J D'Onofrio Chief Executive Officer | UTender of shares Common Stock | -15,509 | - | - | 0 | Dec 17, 2025 |
| Dec 16, 2025 | Marilyn R. Carlson Chief Medical Officer | UTender of shares Common Stock | -360 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Kenneth J Widder director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,187 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Benjamin C. Smeal director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,833 | - | - | 0 | Dec 17, 2025 |
| Dec 16, 2025 | Todd C Brady director | UTender of shares Common Stock | -27 | - | - | 0 | Dec 17, 2025 |
| Dec 16, 2025 | Cam L Garner director | UTender of shares Common Stockindirect: By Garner Investments, L.L.C. | -2,330 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Greg Pyszczymuka director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,155 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Benjamin C. Smeal director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,125 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Kenneth J Widder director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,833 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Cam L Garner director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,479 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Malcolm R Hill director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,218 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Mark Kowieski Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,291 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Vickie S Reed director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,833 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Matthew J D'Onofrio Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -64,840 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Marilyn R. Carlson Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -17,291 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Todd C Brady director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,218 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Todd C Brady director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,833 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Cam L Garner director | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,750 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Malcolm R Hill director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,833 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Kenneth J Widder director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,187 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Mark Kowieski Chief Financial Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -13,000 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Vickie S Reed director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,250 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Matthew J D'Onofrio Chief Executive Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -70,000 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Marilyn R. Carlson Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -11,000 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Malcolm R Hill director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,218 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Todd C Brady director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,187 | - | - | 0 | Dec 17, 2025 |
| Dec 17, 2025 | Cam L Garner director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,291 | - | - | 0 | Dec 17, 2025 |
| Nov 6, 2025 | Roger M. Klein owner | SOpen-market sale Common Stockindirect: By IRA | -5,000 | $10.66 | $53k | 29,000 | Nov 7, 2025 |
| Nov 6, 2025 | Roger M. Klein owner | SOpen-market sale Common Stockindirect: By Krieger Charitable Trust | -4,000 | $10.65 | $43k | 125,000 | Nov 7, 2025 |
| May 21, 2025 | Vickie S Reed director | AGrant or award Stock Option (Right to Buy)derivative | +1,250 | $0.00 | $0 | 8,333 | May 22, 2025 |
| May 21, 2025 | Malcolm R Hill director | AGrant or award Stock Option (Right to Buy)derivative | +1,218 | $0.00 | $0 | 8,269 | May 22, 2025 |
| May 21, 2025 | Cam L Garner director | AGrant or award Stock Option (Right to Buy)derivative | +1,291 | $0.00 | $0 | 11,520 | May 22, 2025 |
| May 21, 2025 | Benjamin C. Smeal director | AGrant or award Stock Option (Right to Buy)derivative | +1,125 | $0.00 | $0 | 6,958 | May 22, 2025 |
| May 21, 2025 | Greg Pyszczymuka director | AGrant or award Stock Option (Right to Buy)derivative | +1,155 | $0.00 | $0 | 6,988 | May 22, 2025 |
| May 21, 2025 | Todd C Brady director | AGrant or award Stock Option (Right to Buy)derivative | +1,187 | $0.00 | $0 | 8,238 | May 22, 2025 |
| May 21, 2025 | Kenneth J Widder director | AGrant or award Stock Option (Right to Buy)derivative | +1,187 | $0.00 | $0 | 8,207 | May 22, 2025 |
| Mar 21, 2025 | Matthew J D'Onofrio Chief Executive Officer | AGrant or award Common Stock | +1,000 | $2.80 | $2,797 | 9,820 | Mar 24, 2025 |
| Mar 20, 2025 | Mark Kowieski Chief Financial Officer | AGrant or award Common Stock | +4,500 | $3.21 | $14k | 4,916 | Mar 24, 2025 |
| Feb 28, 2025 | Matthew J D'Onofrio Chief Executive Officer | AGrant or award Common Stock | +6,849 | $3.65 | $25k | 8,820 | Mar 3, 2025 |
| Feb 20, 2025 | Greg Pyszczymuka director | AGrant or award Stock Option (Right to Buy)derivative | +5,833 | $0.00 | $0 | 5,833 | Feb 24, 2025 |
| Jan 28, 2025 | Nantahala Capital Management, LLC owner | SOpen-market sale Common Stockindirect: See footnote | -41 | $4.39 | $180 | 148,153 | Jan 30, 2025 |
| Jan 28, 2025 | Marilyn R. Carlson Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +11,000 | $0.00 | $0 | 11,000 | Jan 29, 2025 |
| Jan 28, 2025 | Kenneth J Widder director | AGrant or award Stock Option (Right to Buy)derivative | +5,833 | $0.00 | $0 | 5,833 | Jan 29, 2025 |
| Jan 28, 2025 | Malcolm R Hill director | AGrant or award Stock Option (Right to Buy)derivative | +5,833 | $0.00 | $0 | 5,833 | Jan 29, 2025 |
| Jan 28, 2025 | Cam L Garner director | AGrant or award Stock Option (Right to Buy)derivative | +8,750 | $0.00 | $0 | 8,750 | Jan 29, 2025 |
| Jan 28, 2025 | Mark Kowieski Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +13,000 | $0.00 | $0 | 13,000 | Jan 29, 2025 |
| Jan 28, 2025 | Vickie S Reed director | AGrant or award Stock Option (Right to Buy)derivative | +5,833 | $0.00 | $0 | 5,833 | Jan 29, 2025 |
| Jan 28, 2025 | Matthew J D'Onofrio Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Jan 29, 2025 |
| Jan 28, 2025 | Todd C Brady director | AGrant or award Stock Option (Right to Buy)derivative | +5,833 | $0.00 | $0 | 5,833 | Jan 29, 2025 |
| Oct 18, 2024 | Benjamin C. Smeal director | AGrant or award Stock Option (Right to Buy)derivative | +5,833 | $0.00 | $0 | 5,833 | Oct 22, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Todd C Bradyceo, president, officer, director
- Marilyn R. CarlsonChief Medical Officer
- Matthew J D'OnofrioChief Executive Officer
- Cam L Garnerdirector
- Malcolm R Hilldirector
- Roger M. Kleinowner
- Mark KowieskiChief Financial Officer
- Nantahala Capital Management, LLCowner, other
- Greg Pyszczymukaofficer, director
- Vickie S Reeddirector
- Benjamin C. Smealdirector
- Kenneth J Widderdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.